Menarini and Ryvu Report First Dapolsertib Data in Phase II Study

The companies announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed or refractory aggressive B-cell non-Hodgkin lymphoma at the 2026 ASH Annual Meeting.